These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 32170402)

  • 21. IDH1-R132H acts as a tumor suppressor in glioma via epigenetic up-regulation of the DNA damage response.
    Núñez FJ; Mendez FM; Kadiyala P; Alghamri MS; Savelieff MG; Garcia-Fabiani MB; Haase S; Koschmann C; Calinescu AA; Kamran N; Saxena M; Patel R; Carney S; Guo MZ; Edwards M; Ljungman M; Qin T; Sartor MA; Tagett R; Venneti S; Brosnan-Cashman J; Meeker A; Gorbunova V; Zhao L; Kremer DM; Zhang L; Lyssiotis CA; Jones L; Herting CJ; Ross JL; Hambardzumyan D; Hervey-Jumper S; Figueroa ME; Lowenstein PR; Castro MG
    Sci Transl Med; 2019 Feb; 11(479):. PubMed ID: 30760578
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
    Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
    Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mutant IDH1 Cooperates with ATRX Loss to Drive the Alternative Lengthening of Telomere Phenotype in Glioma.
    Mukherjee J; Johannessen TC; Ohba S; Chow TT; Jones L; Pandita A; Pieper RO
    Cancer Res; 2018 Jun; 78(11):2966-2977. PubMed ID: 29545335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical Neuropathology practice news 2-2014: ATRX, a new candidate biomarker in gliomas.
    Haberler C; Wöhrer A
    Clin Neuropathol; 2014; 33(2):108-11. PubMed ID: 24559763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas.
    Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M
    Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
    Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
    J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Primary mismatch repair deficient IDH-mutant astrocytoma (PMMRDIA) is a distinct type with a poor prognosis.
    Suwala AK; Stichel D; Schrimpf D; Kloor M; Wefers AK; Reinhardt A; Maas SLN; Kratz CP; Schweizer L; Hasselblatt M; Snuderl M; Abedalthagafi MSJ; Abdullaev Z; Monoranu CM; Bergmann M; Pekrun A; Freyschlag C; Aronica E; Kramm CM; Hinz F; Sievers P; Korshunov A; Kool M; Pfister SM; Sturm D; Jones DTW; Wick W; Unterberg A; Hartmann C; Dodgshun A; Tabori U; Wesseling P; Sahm F; von Deimling A; Reuss DE
    Acta Neuropathol; 2021 Jan; 141(1):85-100. PubMed ID: 33216206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Isocitrate dehydrogenase-mutant glioma: Evolving clinical and therapeutic implications.
    Miller JJ; Shih HA; Andronesi OC; Cahill DP
    Cancer; 2017 Dec; 123(23):4535-4546. PubMed ID: 28980701
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Diagnostic Value of Conventional MRI and CT Features in the Identification of the IDH1-Mutant and 1p/19q Co-Deletion in WHO Grade II Gliomas.
    Zhao K; Sun G; Wang Q; Xue Z; Liu G; Xia Y; Yao A; Zhao Y; You N; Yang C; Xu B
    Acad Radiol; 2021 Jul; 28(7):e189-e198. PubMed ID: 32359929
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PCR-Based Simple Subgrouping Is Validated for Classification of Gliomas and Defines Negative Prognostic Copy Number Aberrations in IDH Mutant Gliomas.
    Nakae S; Sasaki H; Hayashi S; Hattori N; Kumon M; Nishiyama Y; Adachi K; Nagahisa S; Hayashi T; Inamasu J; Abe M; Hasegawa M; Hirose Y
    PLoS One; 2015; 10(11):e0142750. PubMed ID: 26558387
    [TBL] [Abstract][Full Text] [Related]  

  • 31. IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.
    Etxaniz O; Carrato C; de Aguirre I; Queralt C; Muñoz A; Ramirez JL; Rosell R; Villà S; Diaz R; Estival A; Teixidor P; Indacochea A; Ahjal S; Vilà L; Balañá C
    J Neurooncol; 2017 Nov; 135(2):273-284. PubMed ID: 28884377
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New Molecular Considerations for Glioma: IDH, ATRX, BRAF, TERT, H3 K27M.
    Karsy M; Guan J; Cohen AL; Jensen RL; Colman H
    Curr Neurol Neurosci Rep; 2017 Feb; 17(2):19. PubMed ID: 28271343
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Primary Astrocytic Tumours and Paired Recurrences have Similar Biological Features in IDH1, TP53 and TERTp Mutation and MGMT, ATRX Loss.
    Li X; Wei J; Liu Y; Li P; Fan L; Wang Y; Li M; Zhao D; Yu Z; Ye J; Guo Y; Yan Q; Guo S; Wang Z
    Sci Rep; 2017 Oct; 7(1):13038. PubMed ID: 29026176
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunohistochemical ATRX expression is not a surrogate for 1p19q codeletion.
    Yamamichi A; Ohka F; Aoki K; Suzuki H; Kato A; Hirano M; Motomura K; Tanahashi K; Chalise L; Maeda S; Wakabayashi T; Kato Y; Natsume A
    Brain Tumor Pathol; 2018 Apr; 35(2):106-113. PubMed ID: 29550880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interplay between ATRX and IDH1 mutations governs innate immune responses in diffuse gliomas.
    Hariharan S; Whitfield BT; Pirozzi CJ; Waitkus MS; Brown MC; Bowie ML; Irvin DM; Roso K; Fuller R; Hostettler J; Dharmaiah S; Gibson EA; Briley A; Mangoli A; Fraley C; Shobande M; Stevenson K; Zhang G; Malgulwar PB; Roberts H; Roskoski M; Spasojevic I; Keir ST; He Y; Castro MG; Huse JT; Ashley DM
    Nat Commun; 2024 Jan; 15(1):730. PubMed ID: 38272925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ATRX loss in glioneuronal tumors with neuropil-like islands indicates similarity to diffuse astrocytic tumors.
    Kakkar A; Nambirajan A; Kaur K; Kumar A; Mallick S; Suri V; Sarkar C; Kale SS; Garg A; Sharma MC
    J Neurooncol; 2016 Oct; 130(1):63-68. PubMed ID: 27469217
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Glioma Grading and Determination of IDH Mutation Status and ATRX loss by DCE and ASL Perfusion.
    Brendle C; Hempel JM; Schittenhelm J; Skardelly M; Tabatabai G; Bender B; Ernemann U; Klose U
    Clin Neuroradiol; 2018 Sep; 28(3):421-428. PubMed ID: 28488024
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biphasic IDH1 phenotype in a diffusely infiltrating glioma: implications for pathogenesis, treatment and prognosis.
    Odia Y; Varma H; Tsankova NM
    Clin Neuropathol; 2015; 34(5):282-7. PubMed ID: 25907263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Static and dynamic
    Verger A; Stoffels G; Bauer EK; Lohmann P; Blau T; Fink GR; Neumaier B; Shah NJ; Langen KJ; Galldiks N
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):443-451. PubMed ID: 29043400
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RNA editing-based classification of diffuse gliomas: predicting isocitrate dehydrogenase mutation and chromosome 1p/19q codeletion.
    Chen SC; Lo CM; Wang SH; Su EC
    BMC Bioinformatics; 2019 Dec; 20(Suppl 19):659. PubMed ID: 31870275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.